[EN] INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF [FR] INHIBITEURS DE LA GLYCOGÈNE SYNTHASE 1 (GYS1) ET LEURS MÉTHODES D'UTILISATION
[EN] TRIAZOLONES DERIVATIVES FOR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE<br/>[FR] DÉRIVÉS DE TRIAZOLONES POUR UTILISATION DANS LE TRAITEMENT, LE SOULAGEMENT OU LA PRÉVENTION D'UNE MALADIE VIRALE
申请人:HOFFMANN LA ROCHE
公开号:WO2017046318A1
公开(公告)日:2017-03-23
The present invention relates to a compound having the general formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, tautomer, racemate, codrug, cocrystal, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
A compound having GPR52 agonist activity or a salt thereof is provided.
The compound can be provided as a preventive/therapeutic agent for schizophrenia or the like. The compound is represented by the following formula:
wherein
A represents —CONR
a
— or —NR
a
CO—,
R
a
represents a hydrogen atom or the like,
B represents a hydrogen atom or the like,
a ring Cy1 represents a six-membered aromatic ring which may have one or more substituents in addition to a group represented by -A-B,
a ring Cy2 represents a six-membered ring which may be substituted with a halogen atom or the like,
a ring Cy3 represents a five- or six-membered ring which may have one or more substituents;
X represents C
1-2
alkylene or the like,
m represents an integer of 0 to 2, and
a ring Cy4 represents a six-membered aromatic ring which may have one or more substituents.
The present invention is directed to triazolopyridinone compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.